CD86 and cancer: M-MDSCs have been shown to be enriched in blood and tumors in many cancer patients, including cutaneous melanoma, where they suppress T cell responses.25 Uveal melanoma patients also harbored enhanced levels of CD16+ monocytes (intermediate and non-classical monocytes), which showed signs of enhanced activation as reflected by a higher expression of CD86, HLA-ABC and PD-L1.